|
Q2 FY2026
As of Jun 27, 2026
|
Q1 FY2026
As of Mar 28, 2026
|
Q4 FY2025
As of Dec 27, 2025
|
Q3 FY2025
As of Sep 27, 2025
|
Q2 FY2025
As of Jun 28, 2025
|
Q1 FY2025
As of Mar 29, 2025
|
Q4 FY2024
As of Dec 28, 2024
|
Q3 FY2024
As of Sep 28, 2024
|
Q2 FY2024
As of Jun 29, 2024
|
Q1 FY2024
As of Mar 30, 2024
|
Q4 FY2023
As of Dec 30, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jul 1, 2023
|
Q1 FY2023
As of Apr 1, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 24, 2022
|
Q2 FY2022
As of Jun 25, 2022
|
Q1 FY2022
As of Mar 26, 2022
|
Q4 FY2021
As of Dec 25, 2021
|
Q3 FY2021
As of Sep 25, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Trade receivables and contract assets, net of allowances for credit losses of $8,715 and $10,463, respectively | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid assets | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Venture capital and strategic equity investments | ||||||||||||||||||||
| Operating lease right-of-use assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Client relationships | ||||||||||||||||||||
| Total intangible assets, net | ||||||||||||||||||||
| Deferred tax assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities, Redeemable Noncontrolling Interests and Equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Current portion of long-term debt and finance leases | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt, net and finance leases | ||||||||||||||||||||
| Operating lease right-of-use liabilities | ||||||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Redeemable noncontrolling interests | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding | ||||||||||||||||||||
| Common stock, $0.01 par value; 120,000 shares authorized; 49,550 shares issued and 47,728 shares outstanding as of June 27, 2026, and 49,217 shares issued and outstanding as of December 27, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock, at cost, 104 and zero shares, as of September 30, 2023 and December 31, 2022, respectively | ||||||||||||||||||||
| Treasury stock, at cost, 1,822 and zero shares, as of June 27, 2026 and December 27, 2025, respectively | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total Charles River Laboratories International, Inc. equity | ||||||||||||||||||||
| Nonredeemable noncontrolling interest | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities, redeemable noncontrolling interests and equity | ||||||||||||||||||||
| Beginning balance (in shares) | ||||||||||||||||||||
Loading...
